Open access to a potential new drug target for bowel cancer | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!

Open access to a potential new drug target for bowel cancer

The study, published recently in Developmental Cell, is the work of an international collaboration between Australian, Japanese, US and Canadian researchers led by Professor Colby Zaph, from the Biomedicine Discovery Institute at Monash University. The research is focused on a protein called SETD7, an enzyme that modifies other proteins to affect their function. SETD7 is a central regulator of two of the major pathways to tumorigenesis that merge to create cancerous cells. These two pathways, called the Hippo/YAP and Wnt/beta catenin pathways, have both been highly associated with causing the unlimited growth that is the hallmark of cancers. Research had previously shown that these pathways are related, but the mechanisms that linked them have remained elusive until now. Professor Zaph cautioned that the results are preliminary and decades from being translated but that the patient group most likely to benefit from this research are those with Familial adenomatous polyposis (FAP), a genetic disorder that increases an individual’s chance of developing colon cancer.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.